期刊
REDOX BIOLOGY
卷 25, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.redox.2018.101076
关键词
Metabolic reprogramming; OXPHOS; Oncogene-addiction; STAT3
资金
- National Medical Research Council of Singapore [NMRC/CSA/021/2010]
- NMRC Bench to Bedside (BOB)
- National University Health System Clinician Scientist Program Clinical Science Unit (CSU)
- National Medical Research Council-Clinician Scientist Individual Research Grant [NMRC/CIRG/1433/2015]
The ability to selectively eradicate oncogene-addicted tumors while reducing systemic toxicity has endeared targeted therapies as a treatment strategy. Nevertheless, development of acquired resistance limits the benefits and durability of such a regime. Here we report evidence of enhanced reliance on mitochondrial oxidative phosphorylation (OXPHOS) in oncogene-addicted cancers manifesting acquired resistance to targeted therapies. To that effect, we describe a novel OXPHOS targeting activity of the small molecule compound, OPB-51602 (OPB). Of note, a priori treatment with OPB restored sensitivity to targeted therapies. Furthermore, cancer cells exhibiting stemness markers also showed selective reliance on OXPHOS and enhanced sensitivity to OPB. Importantly, in a subset of patients who developed secondary resistance to EGFR tyrosine kinase inhibitor (TKI), OPB treatment resulted in decrease in metabolic activity and reduction in tumor size. Collectively, we show here a switch to mitochondrial OXPHOS as a key driver of targeted drug resistance in oncogene-addicted cancers. This metabolic vulnerability is exploited by a novel OXPHOS inhibitor, which also shows promise in the clinical setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据